An adult with persistent hypertension (BP 152/92 on two visits). What initial nonpharmacologic and pharmacologic steps should be taken?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Multiple Choice

An adult with persistent hypertension (BP 152/92 on two visits). What initial nonpharmacologic and pharmacologic steps should be taken?

The main idea is that initial management of persistent hypertension combines nonpharmacologic lifestyle changes with starting a first-line antihypertensive, along with baseline labs and outpatient follow-up. For a patient with a sustained BP of 152/92, it’s appropriate to begin treatment by adopting lifestyle modifications such as weight management, regular aerobic exercise, sodium reduction, and limiting alcohol, while also initiating a first-line antihypertensive agent. The first-line options—thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers—are chosen because they have proven cardiovascular benefits and favorable side-effect profiles in uncomplicated hypertension. Starting one of these medications now helps lower blood pressure toward target and reduces cardiovascular risk. Baseline labs are important before or soon after starting therapy to monitor safety and guide follow-up: check kidney function (creatinine) and electrolytes (notably potassium) because some agents affect these values; obtain urinalysis to assess for proteinuria or kidney disease; consider an appropriate lipid panel and glucose assessment given cardiovascular risk. Outpatient follow-up is necessary to assess the BP response, monitor for side effects, and adjust therapy if needed. Why the other approaches aren’t appropriate: starting a high-dose beta-blocker without indication and without lifestyle changes isn’t a standard initial strategy for essential hypertension and risks unnecessary side effects. Observing with no treatment ignores the elevated BP across two visits and leaves cardiovascular risk unaddressed. Jumping straight to two different agents bypasses the stepped, safer approach of starting one first-line agent and titrating as needed based on response and tolerance. In short, begin with lifestyle modifications and a first-line antihypertensive, support with baseline labs, and arrange follow-up to monitor response.

The main idea is that initial management of persistent hypertension combines nonpharmacologic lifestyle changes with starting a first-line antihypertensive, along with baseline labs and outpatient follow-up.

For a patient with a sustained BP of 152/92, it’s appropriate to begin treatment by adopting lifestyle modifications such as weight management, regular aerobic exercise, sodium reduction, and limiting alcohol, while also initiating a first-line antihypertensive agent. The first-line options—thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers—are chosen because they have proven cardiovascular benefits and favorable side-effect profiles in uncomplicated hypertension. Starting one of these medications now helps lower blood pressure toward target and reduces cardiovascular risk.

Baseline labs are important before or soon after starting therapy to monitor safety and guide follow-up: check kidney function (creatinine) and electrolytes (notably potassium) because some agents affect these values; obtain urinalysis to assess for proteinuria or kidney disease; consider an appropriate lipid panel and glucose assessment given cardiovascular risk. Outpatient follow-up is necessary to assess the BP response, monitor for side effects, and adjust therapy if needed.

Why the other approaches aren’t appropriate: starting a high-dose beta-blocker without indication and without lifestyle changes isn’t a standard initial strategy for essential hypertension and risks unnecessary side effects. Observing with no treatment ignores the elevated BP across two visits and leaves cardiovascular risk unaddressed. Jumping straight to two different agents bypasses the stepped, safer approach of starting one first-line agent and titrating as needed based on response and tolerance.

In short, begin with lifestyle modifications and a first-line antihypertensive, support with baseline labs, and arrange follow-up to monitor response.

More practice questions